Business

Announcement on Voluntary Disclosure of the Progress in Phase II Clinical Trial for Innovative Drug UB-221 of the Joint-Stock Company

Announcement on Voluntary Disclosure of the Progress in Phase II Clinical Trial for Innovative Drug UB-221 of the Joint-Stock Company

articleShanghai Shen Lian Biomedical Corporation Class AAugust 31, 20254/news/announcement-on-voluntary-disclosure-of-the-progress-in-phase-ii-clinical-trial-for-innovative-drug-ub-221-of-the-joint-stock-company
Announcement on Voluntary Disclosure of the Progress in Phase II Clinical Trial for Innovative Drug UB-221 of the Joint-Stock Company

About this update from Shanghai Shen Lian Biomedical Corporation Class A

Announcement on Voluntary Disclosure of the Progress in Phase II Clinical Trial for Innovative Drug UB-221 of the Joint-Stock CompanyThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Shanghai Shen Lian Biomedical Corporation Class A